Who was studied, and how
Five numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 23 other studies
164people in the A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes trial, from 2013
140of them with obesity, in this paper
The trial randomly assignedassigned by chance
metformin
placebo
Probably raised BMI z score of 10% or greater from baseline to 26 weeks+17.0
Probably increased gastrointestinal adverse events+36.0
No clear effect on long-term blood sugar−0.30
randomisedthe abstract, start to end
… than placebo (0.1%; mean difference, -0.3% [95% CI, -0.6% to 0.0%]; …
… was 0.2% in each group (mean difference, 0% [95% CI, -0.3% to 0.3%]; …
… in the placebo group (mean difference, 21% [95% CI, 11% to 32%]; P = .003), and 24% (17) of participants in the …
… in the placebo group (mean difference, 36% [95% CI, 19% to 51%]; …
← favours treatmentfavours comparator →
could be chanceReduction in HbA1cmetformin vs placebo
−0.3−0.60 to 0.00
Mean change in HbA1c from baselinemetformin vs placebo
0−0.30 to 0.30
Total daily insulin per kg of body weight was reduced by at least 25% from baselinemetformin vs placebo
2111.0–32.0
Reduction in BMI z score of 10% or greater from baseline to 26 weeksmetformin vs placebo
175.00–29.0
Gastrointestinal adverse eventsmetformin vs placebo
3619.0–51.0
MetforminGlycemic controlBody weight & compositionAdverse events & safety
Metformin × glycemic controlhelps?replicated
unlikelylikely
0.840.84 without it
Metformin × body weight & compositionhelps?mixed
unlikelylikely
0.500.50 without it
Metformin × adverse events & safetyharms?mixed
unlikelylikely
0.270.21 without it
← favours treatmentfavours comparator →
1 / 7